Navigating the choices for diabetes prevention

New England Journal of Medicine

Volumn 362, Issue 16, 2010, Pages 1533-1535

  Nathan, David M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; METFORMIN; NATEGLINIDE; PLACEBO; VALSARTAN;

CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL TRIAL; DIABETES MELLITUS; EDITORIAL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INTERVENTION STUDY; LIFESTYLE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 77951489594     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1002322     Document Type: Editorial

References (11)

1. Crandall JP, Knowler WC, Kahn SF, et al. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008;4:382-393
2. Goldberg RB, Temprosa M, Haffner S, et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009;32:726-732
3. Diabetes Prevention Program Research Group. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-1686 [Erratum, Lancet 2009;374:2054.]
4. The NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-1476
5. Idem. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490
6. Califf RM, Boolell M, Haffner SM, et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 2008;156:623-632
7. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes 2003;52:1475-1484
8. Meigs JB, Nathan DM, D'Agostino RB, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845-1850
9. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-759
10. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-1562
11. Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC. Effect of rosiglitazone and ramipril on β-cell function in people with impaired glucose tolerance or impaired fasting glucose. Diabetes Care 2010;33:608-613